MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$10,206,517
EPS
-$0.43
Unit: Dollar

Income Statement
2025-12-31
General and administrative
2,967,812
Total operating expenses
2,967,812
Loss from operations
-2,967,812
Interest expense, related parties
215,903
Interest income
76,589
Forgiveness of unrelated vendor payables
2,142,297
Change in fair value of deferred underwriting fee - paid in common stock
-196,000
Change in the fair value of warrant liability
-54,312
Loss on exchange of common stock for warrants
-1,740,000
Fair value of common stock to be issued for contingent liability
7,360,000
Total other expense, net
-7,238,705
Net loss
-10,206,517
Basic EPS
-0.43
Diluted EPS
-0.43
Basic Average Shares
23,753,561
Diluted Average Shares
23,753,561
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$10,206,517 Total other expense,net-$7,238,705 Loss from operations-$2,967,812 Forgiveness of unrelatedvendor payables$2,142,297 Interest income$76,589 Change in the fair valueof warrant...-$54,312 Fair value of commonstock to be issued for...$7,360,000 Total operatingexpenses$2,967,812 Loss on exchange ofcommon stock for...-$1,740,000 Interest expense,related parties$215,903 Change in fair value ofdeferred underwriting...-$196,000 General andadministrative$2,967,812

Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma, Inc. (LIMN)